NCT03281538 - Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus | Biotech Hunter

Enrollment

288

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

February 11, 2020

Study Completion Date

February 11, 2020

Conditions

Uremic Pruritus

Interventions

DRUG

CR845

IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)

Trial Locations (27)

11385

Cara Therapeutics Study Site, Ridgewood

11501

Cara Therapeutics Study Site, Mineola

18017

Cara Therapeutics Study Site, Bethlehem

30909

Cara Therapeutics Study Site, Augusta

31701

Cara Therapeutics Study Site, Albany

32789

Cara Therapeutics Study Site, Winter Park

33024

Cara Therapeutics Study Site, Hollywood

33614

Cara Therapeutics Study Site, Tampa

37920

Cara Therapeutics Study Site, Knoxville

48066

Cara Therapeutics Study Site, Roseville

53326

Cara Therapeutics Study Site, Wauwatosa

64131

Cara Therapeutics Study Site, Kansas City

78202

Cara Therapeutics Study Site, San Antonio

78221

Cara Therapeutics Study Site, San Antonio

78229

Cara Therapeutics Study Site, San Antonio

79902

Cara Therapeutics Study Site, El Paso

80230

Cara Therapeutics Study Site, Denver

83642

Cara Therapeutics Study Site, Meridian

84790

Cara Therapeutics Study Site, St. George

87109

Cara Therapeutics Study Site, Albuquerque

87301

Cara Therapeutics Study Site, Gallup

90813

Cara Therapeutics Study Site, Long Beach

91324

Cara Therapeutics Study Site, Northridge

91990

Cara Therapeutics Study Site, Chula Vista

92243

Cara Therapeutics Study Site, El Centro

01107

Cara Therapeutics Study Site, Springfield

00926

Cara Therapeutics Study Site, San Juan